Epac1, PDE4, and PKC protein expression and their association with AKAP95, Cx43, and cyclinD2/E1 in breast cancer tissues

Ping Huang1, Qian Sun2, Wenxin Zhuang2, Kuan Peng2, Dai Wang2, Youliang Yao2, Dongbei Guo2, Lu Zhang2, Chuhan Shen2, Mengyun Sun2, Chaoying Tang2, Bogang Teng2 & Yongxing Zhang2

1 Department of Gynecology, Qilu Hospital of Shandong University, Jinan, China
2 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China

Keywords
AKAP95; association analysis; breast cancer tissue; Epac1; PDE4.

Correspondence
Yongxing Zhang, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 442 Simingnan Road, Xiamen, Fujian 361102, China.
Tel: +86 189 5924 4508
Fax: +86 59 2218 8679
Email: z63y94x@xmu.edu.cn

Received: 17 May 2017; Accepted: 11 June 2017.
doi: 10.1111/1759-7714.12475

Thoracic Cancer 8 (2017) 495–500 © 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Abstract

Background: This study was conducted to investigate the exchange protein directly activated by cAMP (Epac1), PDE4, and PKC expression in breast cancer tissues, and the correlation between these proteins and AKAP95, Cx43, cyclin D2, and cyclin E1.

Methods: PV-9000 two-step immunohistochemistry was used to analyze protein expression.

Results: The positive rate of Epac1 protein expression in breast cancer tissues (58%) was higher than in para-carcinoma tissues (10%) (P < 0.05). There were no significant differences in the positive rates of PDE4 and PKC expression between breast cancer and para-carcinoma tissues (P > 0.05). The positive expression rate of PDE4 was higher in the P53 protein positive group compared to the P53 negative group (P < 0.05). Correlations between Epac1 and cyclin D2, PDE4 and cyclin D2, AKAP95 and PKC, Cx43 and PKC, and cyclin D2 and PKC proteins were observed (P < 0.05).

Conclusion: Epac1 expression in breast cancer tissues was increased, suggesting that the protein may be involved in the development of breast cancer. Correlations between Epac1 and cyclin D2, PDE4 and cyclin D2, AKAP95 and PKC, Cx43 and PKC, and cyclin D2 and PKC proteins suggested synergistic effects among these proteins in the development of breast cancer.

Introduction

Breast cancer is one of the most commonly encountered malignancies in women worldwide. In recent years, breast cancer incidence has been the highest among malignant tumors.5

cAMP levels are directly related to several pathological events noted in different tissues, such as tumor cell proliferation and migration.2-3 The PDE4 enzyme specifically hydrolyzes cAMP and can reduce cAMP levels in the cell, to allow cAMP-dependent proteins to modulate cell signal transduction. The downstream protein of cAMP, namely, Epac1, plays an important role in several biological processes, including cell proliferation. The cAMP/Epac/Rap1 signaling pathway has been shown to be involved in the regulation of the functions of several types of cells, including cell secretion, apoptosis, proliferation, and differentiation. Epac1 and AKAP95 are cAMP dependent proteins involved in a variety of cellular functions.5 A correlation in breast cancer tissues between PDE4, Epac1, and AKAP95 is suspected. Cyclin D and cyclin E proteins can promote cell proliferation at the G1 phase in mammals, while AKAP95 as an intermediary can help cyclin D/E and protein kinase A RII subunits form the complex.6

We hypothesized that there may be a correlation between PDE4, Epac1, PKC, AKAP95, Cx43, and cyclin D/E; therefore, we analyzed the expression of Epac1, PDE4, and PKC proteins in 50 samples of breast cancer using an immunohistochemical method. The relationship between these proteins, and their relationship to AKAP95, Cx43, cyclin E1, and cyclin D2 was analyzed.
Methods

Tumor sources

Tissue samples with definite pathological diagnosis from 50 cases of invasive ductal breast carcinoma were collected from the First Affiliated Hospital of Liaoning Medical University between 2010 and 2011. The patients were aged between 34 and 82 years (mean 55.36 ± 10.64). Twenty-four cases exhibited lymph node metastases, while 26 had no lymph node metastases. The control group samples (n = 10) were collected from tissues over 3 cm distant from cancerous tissue in the 50 breast cancer patients. All adjacent tissues were pathologically examined and cancer cells were not found. All patients provided informed consent. The Medical Ethics Committee of the School of Public Health, Xiamen University, China, approved the study protocol.

Reagents and methods

All specimens were fixed in 10% neutral formaldehyde and paraffin embedded, and then cut into continuous sections 4 μm in diameter. A PV-9000 two-step immunohistochemical staining kit was used for expression analysis (Zhongshan Jin Qiao Biotechnology Co. Ltd., Beijing, China) and the assay was conducted according to the manufacturer's instructions. The assay involved 3,3'-diaminobenzidine-tetrahydrochloride coloring and hematoxylin counterstaining. The rabbit anti-human Epac1 and PKC monoclonal antibody were purchased from Abcam (Cambridge, UK), while the mouse anti-human PDE4A monoclonal antibody was purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Phosphate buffered saline was used as the negative control sample.

Criteria for judging positive expression

A brown–yellow stain indicated positive protein expression, whereas the absence of a brown–yellow stain indicated negative expression. Each section was randomly selected microscopically from 10 different points of view, and 200 tumor cells in each view were counted. The ratio of positive cells to total cells was used to evaluate positive expression, indicated as follows: “−” <10%; “±” ≥10% and <25%; “+” ≥25% and <50%; “++” ≥50% and <75%; and “+++” ≥75%. When the data were statistically processed, “±” and “−” were regarded as negative expression, whereas “+”, “++,” and “+++” were regarded as positive. Epac1 is located in the endomembrane system of cells, immunofluorescence staining of PDE4A of formalin-fixed A-431 cells shows membrane localization, and PKC is located in the cytoplasm, cell membrane, and nucleus.

Statistical analysis

Positive protein expression was analyzed using the χ2 test method. The correlation between protein expressions was evaluated using Spearman’s rank correlation analysis. The test level α was set at 0.05, and the analysis was carried out using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).

Results

Epac1, PDE4, and PKC protein expression in breast cancer tissues

Our group has previously reported on AKAP95, cyclin E1, and Cx43 expression in breast cancer tissues.7 The positive rates of AKAP95 and cyclin E1 protein expression were 78% and 80%, respectively, which were higher than those noted in para-carcinoma tissues. The positive rate of the Cx43 protein was 42%, which was lower than that of the para-carcinoma tissues (P < 0.05). Concomitantly, our previous studies further demonstrated that the positive rate of cyclin D2 protein was 80% in breast cancer tissues (the present study only provides the positive rate of cyclin D2 protein in breast cancer tissue, as no para-carcinoma tissue sample was available).

The Epac1 protein expression levels in the 50 breast cancer samples are shown in Table 1. The positive rate of Epac1 expression in breast cancer was 58% (29/50), which was higher than that noted in the para-carcinoma tissues (10%, 1/10; P < 0.05). The positive rate of PDE4 expression in breast cancer was also 58% (29/50), lower than noted in the para-carcinoma tissues (70%, 7/10). The positive rate of PKC expression in breast cancer tissues was 76% (38/50), while the positive rate of PKC in para-carcinoma tissues was 40% (4/10). No statistical significance in PDE4 and PKC expression between breast cancer and para-carcinoma tissues was observed (P > 0.05) (data not shown). Epac1, PDE4, and PKC were mainly expressed in the cytoplasm of breast cancer tissues, and minimal expression was observed in the nuclei (Fig 1).

Relationship between Epac1, PDE4, and PKC protein expression and clinicopathological features

There were no significant differences in the positive rates of Epac1, PDE4, and PKC protein expression between the
breast cancer tissues with or without lymph node metastasis ($P > 0.05$) (data not shown). We further analyzed the differences between Epac1, PDE4, and PKC protein expression in breast cancer tissues that were negative and positive for estrogen receptor, progesterone receptor, P53, Her-2, and Ki67 markers. Only the positive rate of PDE4 protein in the group positive for P53 was higher compared to the rate in the P53 negative group ($P < 0.05$). No significant difference was found between the other proteins examined (Table 2).

**Correlation between Epac1, PDE4, AKAP95, Cx43, cyclin E1, cyclin D2, and PKC protein expression in breast cancer tissues**

We analyzed the correlation between Epac1, PDE4, and PKC protein expression and their correlation with AKAP95, Cx43, cyclin E1, and cyclin D2 proteins in 50 samples of breast cancer tissues. The results indicated a correlation between Epac1 and cyclin D2 (Table 3), PDE4 and cyclin D2 (Table 4), AKAP95 and PKC (Table 5), Cx43 and PKC (Table 6), and cyclin D2 and PKC (Table 7) ($P < 0.05$). No statistical significance was noted between the other proteins examined (data not shown).

**Discussion**

Epac1 promotes the migration and invasion of pancreatic cancer cells, but it regulates the growth of ovarian cancer cells and promotes the proliferation of prostate cancer via the human serine-threonine-protein/extracellular-signal-regulated-kinase and mammalian target of rapamycin signaling pathways. In the present study, the positive rate of Epac1 expression in breast cancer tissues
was higher than observed in para-carcinoma tissues (10%), suggesting that Epac1 might exert a breast cancer promoting effect, consistent with the results of previous studies.

PDE4 is a member of the cAMP-specific phosphodiesterase family and plays an important role in regulating intracellular cAMP concentration and its downstream signaling. The decreased expression of the PDE4D gene inhibited the proliferation of lung cancer cells with serine/threonine kinase 11 (STK11) mutations, while as a tumor promoting factor, PDE4D played an important role in cancer cell progression. We did not observe any difference in the positive rate of PDE4 protein expression between breast cancer and para-carcinoma tissues. We suspect that histological difference or fewer samples in the control group led to these results. P53 is a tumor suppressor protein. The positive rate of PDE4 was higher in the P53 protein positive group compared to the P53 negative group, suggesting that PDE4 overexpression may induce high expression of the P53 protein in order to balance the cancer promoting effects of the PDE4 protein.

PDE4 protein could regulate the level of cAMP by degrading cAMP. Epac1 and AKAP95 proteins are cAMP-dependent proteins; thus, we speculated that a synergistic effect is present between PDE4, Epac1, and AKAP95 proteins. However, no association between PDE4, Epac1, and AKAP95 proteins was observed in the tissues. Further studies are required in order to verify whether these findings are related to tumorigenesis. A correlation between Epac1 and PDE4 with cyclin D2 protein expression was noted, although cyclin D2 protein is a type of cytogenetic protein, suggesting that both Epac1 and PDE4 proteins were involved in cell cycle progression via cyclin D2.

A multitude of evidence has shown that PKC is involved in a variety of normal and abnormal cell proliferation and differentiation processes, thus confirming that PKC is associated with tumor progression. The deregulated expression of PKC subtypes and the increased activity of the corresponding enzymes exert significant effects in the regulation of cell growth, differentiation, tumor formation, and metastasis processes. Previous studies have shown that PKC-α is highly expressed in prostate, endometrium, advanced bladder, and liver cancer tissues. Although the positive rate of PKC protein in breast cancer tissues was lower than in the para-carcinoma tissues, our results did not indicate the function of breast cancer progression. PKC was associated with the expression of AKAP95, Cx43, and cyclin D2 (P < 0.05), while AKAP95 and cyclin D2 exhibited a cancer promoting effect. Cx43 has been shown to act as a tumor suppressor, suggesting that PKC may be involved in the phosphorylation of AKAP95, Cx43, and cyclin D2 proteins that affects their functional activity and, consequently, the cell cycle process.

There were some limitations to this study. Our sample size was small and we did not conduct any cytological experiments to verify our results.

Epac1 expression in breast cancer tissues was increased, suggesting that the protein may be involved in the

### Table 2: Relationship between P53 and PDE4, Epac1, and PKC proteins in breast cancer

|          | PDE4 | Epac1 | PKC |
|----------|------|-------|-----|
| Positive |      |       |     |
| Negative |      |       |     |

### Table 3: Analysis of the correlation between Epac1 and cyclin D2 protein expression in breast cancer

| Cyclin D2 | − | ++ | +++ | rs† | P  |
|-----------|---|----|-----|-----|----|
| −         | 1 | 2  | 0   | 0.376 | 0.009 |
| ++        | 2 | 0  | 2   | 1    | 0.376 | 0.009 |
| +++       | 7 | 2  | 7   | 7    | 0.376 | 0.009 |

### Table 4: Analysis of the correlation between PDE4 protein and cyclin D2 protein expression in breast cancer tissues

| Cyclin D2 | − | + | ++ | +++ | rs† | P  |
|-----------|---|---|----|-----|-----|----|
| −         | 0 | 2 | 1  | 1   | 0.396 | 0.006 |
| +         | 4 | 3 | 4  | 2   | 0.396 | 0.006 |
| ++        | 1 | 0 | 10 | 4   | 0.396 | 0.006 |
| +++       | 0 | 0 | 0  | 0   | 0.396 | 0.006 |

### Table 5: Analysis of the correlation between AKAP95 protein and PKC protein expression in breast cancer

| PKC       | − | + | ++ | +++ | rs† | P  |
|-----------|---|---|----|-----|-----|----|
| −         | 1 | 0 | 0  | 1   | 0.391 | 0.006 |
| +         | 2 | 3 | 2  | 2   | 0.391 | 0.006 |
| ++        | 3 | 3 | 5  | 5   | 0.391 | 0.006 |
| +++       | 0 | 0 | 2  | 0   | 0.391 | 0.006 |

†rs is the Spearman rank correlation coefficient.
development of breast cancer. The positive rate of PDE4 in the P53 protein positive group was higher compared to the P53 negative group, implying that PDE4 overexpression may induce high P53 protein expression. In addition, the correlations between Epac1 and cyclin D2, PDE4 and cyclin D2, AKAP95 and PKC, Cx43 and PKC, and cyclin D2 and PKC proteins suggested synergistic effects among these proteins in the development of breast cancer.

Acknowledgments

This work was supported by the Natural Science Foundation of Fujian Province of China (No. 2016J01407), the National Natural Science Foundation (No. 31370166), the Key Research and Development Program of Shandong Province (grant No. 2015GSF118148), and Xiamen University Training Programs of Innovation and Entrepreneurship for Undergraduates (No. 2016X0433 and No. 2015X0453).

Disclosure

No authors report any conflict of interest.

References

1. Luo N, Qu Y-Q, Dong R. The treatment progress of the breast cancer. Progress in Modern Biomedicine 2015; 13: 160–2.
2. Zimmerman NP, Roy I, Hauser AD, Wilson JM, Williams CL, Dwinell MB. Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol Carcinog 2015; 54: 203–15.
3. Yang Z, Tsuchiya H, Zhang Y, Hartnett ME, Wang L. MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. J Biol Chem 2013; 288: 28893–9.
4. A M, Gil C. cAMP-specific phosphodiesterase inhibitors: Promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat 2014; 24: 1311–21.
5. Jeyaraj SC, Unger NT, Chotani MA. Rap1 GTPases: An emerging role in the cardiovasculature. Life Sci 2011; 88: 645–52.
6. Arsenijevic T, Degraef C, Dumont JE, Roger PP, Pirson I. G1/S cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95. Cell Cycle 2006; 5: 1217–22.
7. Wei QY, Dai Y, Hua SH et al. Correlation analysis between the protein expression of AKAP95, cyclin E, and Cx43 in breast cancer. Int J Clin Exp Pathol 2016; 9: 216–22.
8. Almahariq M, Tsalkova T, Mei FC et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol 2013; 83: 122–8.
9. Gao M, Ma Y, Bast RC Jr et al. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/cyclin D1/CDK4 pathway in vitro and in vivo. Med Oncol 2016; 33: Article: 73.
10. Misra UK, Pizzo SV. Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem 2009; 108: 998–1011.
11. He N, Kim N, Song M et al. Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. Mol Cancer Ther 2014; 13: 2463–73.
12. Lin DC, Xu L, Ding LW et al. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A 2013; 110: 6109–14.
13. Furihata M, Ohtsuki Y, Sonobe H et al. Prognostic significance of cyclin E and p53 protein overexpression in cancer of the renal pelvis and ureter. Br J Cancer 1998; 77: 783–8.
14. Li M, Zhou JY, Ge Y, Matherly LH, GS W. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 2003; 278: 41059–68.
15. Kang KB, Zhu C, Yong SK, Gao Q, Wong MC. Enhanced sensitivity of celexobix in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol Cancer 2009; 8: 66.
16. Zhou J, Tian Y, Li J et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 433: 207–12.
17 Zhang L, Liu X, Jin H et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett 2013; 332: 94–101.

18 Wang G, Zhao Y, Liu X et al. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular cancer. Genes Chromosomes Cancer 2001; 31: 221–7.

19 Yu X, Yuan Y, Zhi X et al. Correlation between the protein expression of A-kinase anchor protein 95, cyclin D3 and AKT and pathological indicators in lung cancer tissues. Exp Ther Med 2015; 10: 1175–81.

20 Qi F, Yuan Y, Zhi X et al. Synergistic effects of AKAP95, cyclin D1, cyclin E1, and Cx43 in the development of rectal cancer. Int J Clin Exp Pathol 2015; 8: 1666–73.

21 Zariwala M, Liu J, Xiong Y. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. Oncogene 1998; 17: 2787–98.

22 Zhang YW, Morita I, Ikeda M, Ma KW, Murota S. Connexin-43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene 2001; 20: 4138–49.